Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linna Wang

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
Kidney International|June 25, 2018
Youthful systemic milieu alleviates renal ischemia-reperfusion injury in elderly miceDong Liu, Lide Lun, Qi Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Jia Wei, Feng Wang, et al.
Aging|April 13, 2019
Exogenous biological renal support ameliorates renal pathology after ischemia reperfusion injury in elderly miceDong Liu, Zhiwei Yin, Qi Huang, et al.
Pharmacological Research|November 11, 2022
The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritisJiujie Yang, Zhi Li, Linna Wang, et al.
Pharmaceutical Research|July 31, 2023
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug InteractionsJessica Chu, Erika Panfen, Linna Wang, et al.
The Lancet. Oncology|March 1, 2020
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trialShukui Qin, Zhenggang Ren, Zhiqiang Meng, et al.
Liver Cancer|November 1, 2021
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined ProgressionZhenggang Ren, Shukui Qin, Zhiqiang Meng, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 4, 2022
An integrative analysis of Qingfei Paidu Decoction for its anti-HCoV-229E mechanism in cold and damp environment based on the pharmacokinetics, metabolomics and molecular docking technologyYan Zhang, Xinru Gu, Yanyan Zhou, et al.
Data in Brief|January 21, 2026
Characterization of the complete mitochondrial genome data of the allotriploid grouper <i>Epinephelus fuscoguttatus</i> ♀× <i>Epinephelus tukula</i> ♂Zhentong Li, Linlin Li, Yuan Deng, et al.
Clinical Immunology (Orlando, Fla.)|December 8, 2023
Huanglian Jiedu Wan intervened with "Shi-Re Shanghuo" syndrome through regulating immune balance mediated by biomarker succinateKeke Luo, Haiyu Zhao, Mengxiao Wang, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
Kidney International|June 25, 2018
Youthful systemic milieu alleviates renal ischemia-reperfusion injury in elderly miceDong Liu, Lide Lun, Qi Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Jia Wei, Feng Wang, et al.
Aging|April 13, 2019
Exogenous biological renal support ameliorates renal pathology after ischemia reperfusion injury in elderly miceDong Liu, Zhiwei Yin, Qi Huang, et al.
Pharmacological Research|November 11, 2022
The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritisJiujie Yang, Zhi Li, Linna Wang, et al.
Pharmaceutical Research|July 31, 2023
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug InteractionsJessica Chu, Erika Panfen, Linna Wang, et al.
The Lancet. Oncology|March 1, 2020
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trialShukui Qin, Zhenggang Ren, Zhiqiang Meng, et al.
Liver Cancer|November 1, 2021
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined ProgressionZhenggang Ren, Shukui Qin, Zhiqiang Meng, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|November 4, 2022
An integrative analysis of Qingfei Paidu Decoction for its anti-HCoV-229E mechanism in cold and damp environment based on the pharmacokinetics, metabolomics and molecular docking technologyYan Zhang, Xinru Gu, Yanyan Zhou, et al.
Data in Brief|January 21, 2026
Characterization of the complete mitochondrial genome data of the allotriploid grouper <i>Epinephelus fuscoguttatus</i> ♀× <i>Epinephelus tukula</i> ♂Zhentong Li, Linlin Li, Yuan Deng, et al.
Clinical Immunology (Orlando, Fla.)|December 8, 2023
Huanglian Jiedu Wan intervened with "Shi-Re Shanghuo" syndrome through regulating immune balance mediated by biomarker succinateKeke Luo, Haiyu Zhao, Mengxiao Wang, et al.
Pageof 16